Analystreport

Sarepta Therapeutics, Inc. (NASDAQ: SRPT) was upgraded by analysts at UBS Group AG from a "neutral" rating to a "buy" rating.

Sarepta Therapeutics, Inc.  (SRPT) 
Last sarepta therapeutics, inc. earnings: 2/26 04:05 pm Check Earnings Report